arrow_back Back to App

Opioid Fee on Manufacturers Funds Addiction Treatment and Patient Care.

This law establishes a new fee of 1 cent per milligram on manufacturers and importers of active opioid pain relievers. The revenue generated will be exclusively dedicated to funding state substance abuse treatment programs, including building new facilities and expanding services. Crucially, mechanisms are mandated to ensure that eligible patients, such as those with cancer or in hospice care, receive rebates or discounts so they do not bear the economic burden of this new fee.
Key points
A new fee of 1 cent per milligram is imposed on manufacturers and importers of active opioid pain relievers.
All revenue collected (minus patient rebates) is earmarked for expanding state substance abuse and opioid addiction treatment efforts.
Cancer patients, hospice patients, and others with specific medical needs are protected from paying the fee through mandatory rebate or discount programs.
Funds will support establishing new treatment centers, sober living facilities, and care for infants born with neonatal abstinence syndrome.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_2559
Sponsor: Sen. Manchin, Joe, III [D-WV]
Process start date: 2023-07-27
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Budgeting for Opioid Addiction Treatment Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_2559.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-07-27.

What are the main provisions?

Key points include:

  • A new fee of 1 cent per milligram is imposed on manufacturers and importers of active opioid pain relievers.
  • All revenue collected (minus patient rebates) is earmarked for expanding state substance abuse and opioid addiction treatment efforts.
  • Cancer patients, hospice patients, and others with specific medical needs are protected from paying the fee through mandatory rebate or discount programs.
  • Funds will support establishing new treatment centers, sober living facilities, and care for infants born with neonatal abstinence syndrome.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Manchin, Joe, III [D-WV].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Taxes Health